Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck

British Journal of Cancer

Volumn 72, Issue 1, 1995, Pages 123-128

  Kiaris, H ^a,b   Spandidos, D A ^b,c   Jones, A S ^a   Vaughan, E D ^a,d   Field, J K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF CRETE   (Greece)

^c INSTITUTE OF BIOLOGY   (Greece)

^d Walton Hospital   (United Kingdom)

Author keywords

H ras expression; Oral cancer; Ras mutations; Squamous cell carcinoma of the head and neck

Indexed keywords

MESSENGER RNA;

ARTICLE; CANCER RISK; CODON; GENE EXPRESSION; GENE MUTATION; GENOME; HEAD AND NECK CARCINOMA; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE H RAS; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; VARIABLE NUMBER OF TANDEM REPEAT;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HEAD AND NECK NEOPLASMS; HUMAN; MOLECULAR SEQUENCE DATA; MUTATION; REPETITIVE SEQUENCES, NUCLEIC ACID; RNA, MESSENGER;

EID: 0029060026     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.287     Document Type: Article

References (38)

1. AZUMA M, FURUMOTO N, KAWAMATA H, YOSHIDA H, YANAGAWA T, YURA Y, HAYASHI Y, TAKEGAWA Y, AND SATO M. (1987). The relation of ras oncogene product p21 expression to clinicopathological status criteria and clinical outcome in squamous cell head and neck cancer. Cancer J., 1, 375–380.
2. BARBACID M. (1987). Ras genes. Annu. Rev. Biochem., 56, 779–827.
3. BOGUSKI MS, AND McCORMICK F. (1993). Proteins regulating Ras and its relatives. Nature, 366, 643 -654.
4. BOS JL. (1989). Ras oncogenes in human cancer: A review. Cancer Res., 49, 4682–4689.
5. BREATHNACH R, AND CHAMBON P. (1981). Organization and expression of eukaryotic split genes coding for proteins. Annu. Rev. Biochem., 50, 349–383.
6. CHANG SE, BHATIA P, JOHNSON PR, MCCORMICK F, YOUNG B, AND HIORNS L. (1991). Ras mutations in United Kingdom examples of oral malignancies are infrequent. Int. J. Cancer, 48, 409–412.
7. CLARK LJ, EDINGTON K, SWAN IR, MCLAY KA, NEWLANDS WJ, WILLS LC, YOUNG HA, JOHNSTON PW, MITCHELL R, ROBERTSON G, AND OTHERS. (1993). The absence of Harvey ras mutations during development and progression of squamous cell carcinomas of the head and neck. Br. J. Cancer, 68, 617–620.
8. COLEMAN WB, THRONEBURG DB, GRISHAM JW, AND SMITH GJ. (1994). Overexpression of c-K-ras, c-N-ras and transforming growth factor 0 co-segregate with tumorigenicity in morphologically transformed C3H 10T1/2 cell lines. Carcinogenesis, 15, 1005–1012.
9. FIELD JK. (1992). Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Eur. J. Cancer Oral Oncol., 28B, 67–76.
10. HELD JK, AND SPANDIDOS DA. (1990). The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis. A revew. Anticancer Res., 10, 1–22.
11. FIELD JK, LAMOTHE A, AND SPANDIDOS DA. (1986). Clinical relevance of oncogene expression in head and neck tumours. Anticancer Res., 6, 595–600.
12. HELD JK, YIAGNISIS M, SPANDIDOS DA, GOSNEY JR, PAPADIMITRIOU K, VAUGHAN ED, AND STELL PM. (1992). Low leves of ras p21 oncogene expression correlates with clinical outcome in head and neck squamous cell carcinoma. Eur. J. Surg. Oncol., 18, 168–176.
13. FOLEY KP, LEONARD MW, AND ENGEL JD. (1993). Quantitation of RNA using the polymerase chain reaction. Trends Genet., 9, 380–385.
14. GARCIA I, DIETRICH P-Y, AAPRO M, VAUTHIER G, VADAS L, AND ENGEL E. (1989). Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras-1 protooncogenes and clinical associations in human breast carcinomas. Cancer Res., 49, 6675 -6679.
15. GREEN M, AND KRONTIRIS TG. (1993). Allelic variation of reporter gene activation by the HRAS1 minisatellite. Genomics, 17, 429–434.
16. HIRANO T, STEELE PE, AND GULCKMAN JL. (1991). Low incidence of point mutation at codon 12 of K-ras proto-oncogene in squamous cell carcinoma of the upper aerodigestive tract. Ann. Otol. Rhinol. Laryngol., 100, 597–599.
17. HONKAWA H, MASAHASHI W, HASHIMOTO S, AND HASHIMOTOGOTOH T. (1987). Identification of the principal promoter sequence of the c-H-ras transforming oncogene: Deletion analysis of the 5’-flanking region by focus formation assay. Mol. Cell Biol., 7, 2933–2940.
18. HONKAWA H, MASAHASHI W, HASHIMOTO S, AND HASHIMOTOGOTOH T. (1987). Identification of the principal promoter sequence of the c-H-ras transforming oncogene: Deletion analysis of the 5’-fianking region by focus formation assay. Mol. Cell Biol., 7, 2933–2940.
19. HOWELL RE, WONG FS, AND FENWICK RG. (1989). Loss of Harvey ras heterozygosity in oral squamous carcinoma. J. Oral Pathol., 18, 79–83.
20. KIARIS H, SPANDIDOS DA, JONES AS, AND FIELD JK. (1994). Loss of heterozygosity and microsatellite instability of the H-ras gene in cancer of the head and neck. Int. J. Oncol., 5, 579–582.
21. KOTSINAS A, KIARIS H, AND SPANDIDOS DA. (1994). A method to detect and quantitate the expression of normal versus mutant H-ras transcripts at codon 12. Int. J. Oncol., 5, 479–483.
22. KRONTIRIS TG, DEVLIN B, KARP DD, ROBERT NJ, AND RISCH N. (1993). An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N. Engl. J. Med., 329, 517–523.
23. KUO MYP, JENG JH, CHIANG CP, AND HAHN U. (1994). Mutations of Ki-ras oncogene codon 12 in betel quid chewing-related human oral squamous cell carcinoma in Taiwan. J. Oral. Pathol. Med., 23, 70–74.
24. RUMSBY G, CARTER RL, AND GUSTERSON BA. (1990). Low incidence of ras-oncogene activation in human squamous cell carcinomas. Br. J. Cancer, 61, 365 -368.
25. SARANATH D, CHANG SE, BHOITE IT, PANCHAL RG, KERR IB, MEHTA AR, JOHNSON NW, AND DEO MG. (1991). High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br. J. Cancer, 63, 573–578.
26. SCAMBIA G, CATOZZI L, BENEDETTI PANICI P, FERRANDINA G, ALMADORI G, PALUDETTI G, CADONI G, DISTEFANO M, PIFFANELLI A, MANCUSO S, AND MAURIZI M. (1994). Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: Correlation with histopathological features and epidermal growth factor receptors. Br. J. Cancer, 69, 959 -999.
27. SHENG ZM, BARROIS M, KLIJANIENKO J, MICHEAU C, RICHARD JM, AND RIOU G. (1990). Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas. Br. J. Cancer, 62, 398 -404.
28. SHIRAISHI M, MORINAGA S, NOGUCHI M, SHIMOSATO Y, AND SEKJYA T. (1987). Loss of genes on the short arm of chromosome 11 in human lung carcinomas. Jpn J. Cancer Res., 78, 1302–1308.
29. SPANDIDOS DA, FRAME M, AND WILKIE NM. (1990). Expression of the normal H-ras 1 gene can suppress the transformed and tumorigenic phenotypes induced by mutant ras genes. Anticancer Res., 10, 1543–1554.
30. SPANDIDOS DA, AND HOLMES L. (1987). Transcriptional enhancer activity in the variable tandem repeat DNA sequence downstream of the human Ha-ras-1 gene. FEBS Lett., 218, 41–46.
31. SPANDIDOS DA, AND WILKIE NM. (1984). Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature, 310, 469–475.
32. SPANDIDOS DA, LAMOTHE A, AND FIELD JK. (1985). Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours. Anticancer Res., 5, 221–224.
33. TSUJI T, SASAKI K, HIRAOKA F, AND SHINOZAKI F. (1989). The immunohistochemical detection of ras p21 and its correlation with differentiation in oral cancers. J. Tumour Marker Oncol., 4, 415–419.
34. UICC. (1978). TNM Classification of Malignant Tumours, Harmer MN. (ed.) UICC: Geneva.
35. VACHTENHEIM J, HORAKOVA I, AND NOVOTNA H. (1994). Hypomethylation of CCGG sites in the 3’-region of H-ras protooncogene is frequent and is associated with H-ras allele loss in non-small cell lung cancer. Cancer Res., 54, 1145–1148.
36. VOKES EE, WEICHSELBAUM RR, LIPPMAN SM, AND HONG WK. (1993). Head and neck cancer. N. Engl. J. Med., 328, 184–194.
37. WARNAKULSURIYA KAAS, CHANG SE, AND JOHNSON NW. (1992). Point mutations in the Ha-ras oncogene are detectable in formalin-fixed tissues of oral squamous cell carcinomas, but are infrequent in British cases. J. Oral. Pathol. Med., 21, 225–229.
38. YEUDALL WA, TORRANCE LK, ELSEGOOD KA, SPEIGHT P, SCULLY C, AND PRIME SS. (1993). ras Gene point mutation is a rare event in premalignant tissues and malignant cells and tissues from oral mucosal lesions. Eur. J. Cancer Oral Oncol., 29B, 63–67.